An ethical framework for human embryology with embryo models.

blastoids definition embryo embryo models embryology ethics gastruloids human legal

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
17 08 2023
Historique:
received: 28 01 2023
revised: 24 04 2023
accepted: 18 07 2023
medline: 21 8 2023
pubmed: 19 8 2023
entrez: 18 8 2023
Statut: ppublish

Résumé

A human embryo's legal definition and its entitlement to protection vary greatly worldwide. Recently, human pluripotent stem cells have been used to form in vitro models of early embryos that have challenged legal definitions and raised questions regarding their usage. In this light, we propose a refined legal definition of an embryo, suggest "tipping points" for when human embryo models could eventually be afforded similar protection to that of embryos, and then revisit basic ethical principles that might help to draft a roadmap for the gradual, justified usage of embryo models in a manner that aims to maximize benefits to society.

Identifiants

pubmed: 37595564
pii: S0092-8674(23)00807-3
doi: 10.1016/j.cell.2023.07.028
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3548-3557

Subventions

Organisme : Cancer Research UK
ID : CC2186
Pays : United Kingdom
Organisme : Medical Research Council
ID : CC2186
Pays : United Kingdom
Organisme : Wellcome Trust
ID : CC2186
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V005367/2
Pays : United Kingdom

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests N.C.R. is an inventor on the patents “Blastoid, cell line based artificial blastocyst” (EP2986711) and “Blastocyst-like cell aggregate and methods” (EP21151455.9) that are both licensed to dawn-bio, a company he co-founded. A.M.A. and N.M. are inventors on the patents "Polarised three-dimensional cellular aggregates” (PCT/GB2019/052668) and “human polarised three-dimensional cellular” (PCT/GB2019/052670), maintained by Cambridge Enterprise.

Auteurs

Nicolas C Rivron (NC)

Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna Biocenter (VBC), 1030 Vienna, Austria. Electronic address: nicolas.rivron@imba.oeaw.ac.at.

Alfonso Martinez Arias (A)

Systems Bioengineering, DCEXS, Universidad Pompeu Fabra, Doctor Aiguader 88 ICREA (Institució Catalana de Recerca i Estudis Avançats), Barcelona, Spain.

Martin F Pera (MF)

The Jackson Laboratory, Bar Harbor, ME, USA.

Naomi Moris (N)

The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK.

Hafez Ismaili M'hamdi (HI)

Department of Medical Ethics, Philosophy and History of Medicine, Erasmus MC, University Medical Centre, Rotterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH